Floatz logo

TPX 0131

Metastatic Solid Tumor

Turning Point Therapeutics, Inc.Small moleculePhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

132 Active assets in the Metastatic Solid Tumor cohort.

Asset / SponsorPhaseRating
Epirubicin
InSilico Medicine Hong Kong Limited
Phase 2CCC
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2CCC
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2CCC
Nivolumab
Lantern Pharma Inc.
Phase 2CCC
Trastuzumab Emtansine
M.D. Anderson Cancer Center
Phase 2CCC

View all 50 →

Same molecule, other indications

TPX 0131 is also rated in:

ALK Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →